While most hormonal-based therapies for breast cancer involve inhibiting estrogen receptor (ER)-signaling in hormone receptor positive subtypes, it has recently come to light that AR-signaling is likely an important modulator of breast cancer cell survival and may also be a viable target [55,56]. Here, ESR1 is linked to breast carcinoma.